Strategic partnership to rapidly bring monkeypox test kits to market

A strategic partnership between WeTrade Group and Jiqing Biomedical Technology hopes to rapidly bring monkeypox virus test kits to market and open antigen test sale channels. 

As an innovative biotechnology company, Jiqing focuses on medical research and experimental development with an emphasis on technological innovation. In response to the COVID-19 pandemic, Jiqing created an antigen self-test kit fully approved by the EU, with subsequent product registration certificates obtained for countries including the UK MHRA, Thailand FD, EU CE, German Bfarm, Netherlands CIBG, and Malaysia MDA. With the emergence and spread of monkeypox, Jiqing developed a nucleic acid RT-LAMP test and a colloidal gold technique antigen test.  

Working with Jiqing, WeTrade Group will leverage its digital tools to rapidly bring monkeypox virus test kits to market with the power of YCloud, a cloud intelligent system for microbusinesses, and its industry accumulation in computer technology and big data.  

CEO of WeTrade Group Piun Liu stated: “The COVID pandemic has caused tremendous harm to the public and the monkeypox has caused significant impact on people in several countries. To solve the issue, we are looking forward to the cooperation between us and Jiqing. We hope to bring the two monkeypox virus test kits to the market as soon as possible by technology empowerment to help prevent and control the virus, and to reduce the harm for the public worldwide.” 

Source: WeTrade Group Announced a Strategic Partnership with Jiqing Bio Company, to Exclusively Sell Monkeypox Test Kits and Antigen Tests (prnewswire.com)